COVID-19: Oxford’s vaccine trials to continue after a subject’s death
Category: #health  By Nikita Chaurasia  Date: 2020-10-23
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

COVID-19: Oxford’s vaccine trials to continue after a subject’s death
  • The deceased volunteer was reportedly subjected to a placebo and not the actual COVID-19 vaccine.
  • The Brazilian government plans on purchasing the patent COVID-19 vaccine if approved.

According to reliable sources, the demise of a volunteer occurred during AstraZeneca’s and Oxford’s COVID-19 trials, currently being conducted in Brazil. Following the review of the of the unfortunate event, health surveillance authority Anvisa (Agência Nacional de Vigilância Sanitária) has reportedly authorized the study to proceed without any disruptions.

The deceased volunteer was subjected to a placebo and not the actual COVID-19 vaccine, sources confirmed. In fact, the effectuality of the potential vaccine was evaluated on only half of the volunteers participating in the trial.

In this context, AstraZeneca issued a statement claiming that all the medical events are carefully monitored by trial investigators along with an independent safety monitoring committee. Providing assurance regarding the authenticity of the trials, the company further stated that it had followed all the prerequisite review processes.

According to the University of Oxford, all significant medical incidents, including those concerning the participants in the control group or the COVID-19 vaccine group, are reviewed independently.

It is to be noted that AstraZeneca conducted its phase 1 and 2 trials for the potential vaccine candidate, while the phase 3 trial is currently being carried out in India, Brazil, and in the United Kingdom.

Reportedly, the Brazilian regulator has suggested that the companies to continue their trial round. Moreover, the Brazilian government plans on purchasing the patent COVID-19 vaccine if it is approved by the regulatory bodies.

Meanwhile, Brazil’s President Jair Bolsonaro has reportedly declared that the federal government will not buy a COVID-19 vaccine from China-based biopharmaceutical company Sinovac Biotech Ltd.

 

Source credits: https://www.bbc.com/news/world-latin-america-54634518

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...